SE460539B - Hybrida humanleukocyt interferoner, dna-sekvens kodande foer dem, vektor innehaallande dna-sekvensen samt farmaceutisk komposition innehaallande hybrida humanleukocytinterferonerna - Google Patents

Hybrida humanleukocyt interferoner, dna-sekvens kodande foer dem, vektor innehaallande dna-sekvensen samt farmaceutisk komposition innehaallande hybrida humanleukocytinterferonerna

Info

Publication number: SE460539B
Authority: SE; Sweden
Prior art keywords: leif; fragment; amino acids; amino acid; trp
Prior art date: 1980-11-10

Application number

SE8106641A

Other languages

English (en)

Swedish (sv)

Other versions

SE8106641L (sv

Inventor

D V N Goeddel

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-11-10

Filing date

1981-11-09

Publication date

1989-10-23

1981-02-23 Priority claimed from US06/237,388 external-priority patent/US4414150A/en

1981-09-25 Priority claimed from US06/305,657 external-priority patent/US4456748A/en

1981-11-09 Application filed by Genentech Inc filed Critical Genentech Inc

1982-06-24 Publication of SE8106641L publication Critical patent/SE8106641L/

1989-10-23 Publication of SE460539B publication Critical patent/SE460539B/sv

Links

239000008194 pharmaceutical composition Substances 0.000 title claims 2
239000013598 vector Substances 0.000 title abstract description 4
108091028043 Nucleic acid sequence Proteins 0.000 title description 5
108010050904 Interferons Proteins 0.000 claims abstract description 57
102000014150 Interferons Human genes 0.000 claims abstract description 56
229940047124 interferons Drugs 0.000 claims abstract description 35
210000000265 leukocyte Anatomy 0.000 claims abstract description 24
238000004519 manufacturing process Methods 0.000 claims abstract description 4
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
239000012634 fragment Substances 0.000 claims description 137
150000001413 amino acids Chemical class 0.000 claims description 75
239000013612 plasmid Substances 0.000 claims description 65
108020004414 DNA Proteins 0.000 claims description 37
102100040018 Interferon alpha-2 Human genes 0.000 claims description 36
108010078049 Interferon alpha-2 Proteins 0.000 claims description 36
229920001184 polypeptide Polymers 0.000 claims description 28
108090000765 processed proteins & peptides Proteins 0.000 claims description 28
102000004196 processed proteins & peptides Human genes 0.000 claims description 28
108091008146 restriction endonucleases Proteins 0.000 claims description 24
238000003776 cleavage reaction Methods 0.000 claims description 23
230000007017 scission Effects 0.000 claims description 23
108010047761 Interferon-alpha Proteins 0.000 claims description 21
108020004705 Codon Proteins 0.000 claims description 20
102000006992 Interferon-alpha Human genes 0.000 claims description 19
230000029087 digestion Effects 0.000 claims description 18
229940079322 interferon Drugs 0.000 claims description 18
230000000840 anti-viral effect Effects 0.000 claims description 15
102100040019 Interferon alpha-1/13 Human genes 0.000 claims description 14
102000053602 DNA Human genes 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
239000003981 vehicle Substances 0.000 claims description 10
244000005700 microbiome Species 0.000 claims description 8
101001034833 Homo sapiens Interferon alpha-21 Proteins 0.000 claims description 4
102100039729 Interferon alpha-21 Human genes 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
239000004576 sand Substances 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 6
230000000813 microbial effect Effects 0.000 abstract description 5
108020004511 Recombinant DNA Proteins 0.000 abstract description 3
230000003612 virological effect Effects 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 62
ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 61
MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 55
235000004279 alanine Nutrition 0.000 description 49
235000001014 amino acid Nutrition 0.000 description 44
229940024606 amino acid Drugs 0.000 description 43
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 37
235000013922 glutamic acid Nutrition 0.000 description 37
239000004220 glutamic acid Substances 0.000 description 37
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 36
230000000694 effects Effects 0.000 description 36
OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 35
XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 35
235000003704 aspartic acid Nutrition 0.000 description 35
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 35
210000004027 cell Anatomy 0.000 description 34
CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 29
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 26
239000000047 product Substances 0.000 description 25
239000004098 Tetracycline Substances 0.000 description 24
229960002180 tetracycline Drugs 0.000 description 24
229930101283 tetracycline Natural products 0.000 description 24
235000019364 tetracycline Nutrition 0.000 description 24
150000003522 tetracyclines Chemical class 0.000 description 24
HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 23
235000018417 cysteine Nutrition 0.000 description 22
238000000034 method Methods 0.000 description 22
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 20
239000013613 expression plasmid Substances 0.000 description 19
241000588724 Escherichia coli Species 0.000 description 17
239000002773 nucleotide Substances 0.000 description 16
125000003729 nucleotide group Chemical group 0.000 description 16
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 12
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 12
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 12
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 12
241000894006 Bacteria Species 0.000 description 10
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 9
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
235000009582 asparagine Nutrition 0.000 description 9
229960001230 asparagine Drugs 0.000 description 9
241001646716 Escherichia coli K-12 Species 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
241000711975 Vesicular stomatitis virus Species 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000010276 construction Methods 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 7
239000000523 sample Substances 0.000 description 7
241000700605 Viruses Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
229960000723 ampicillin Drugs 0.000 description 5
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000000120 cytopathologic effect Effects 0.000 description 5
238000012869 ethanol precipitation Methods 0.000 description 5
238000000605 extraction Methods 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000009385 viral infection Effects 0.000 description 5
102000012410 DNA Ligases Human genes 0.000 description 4
108010061982 DNA Ligases Proteins 0.000 description 4
108010017826 DNA Polymerase I Proteins 0.000 description 4
102000004594 DNA Polymerase I Human genes 0.000 description 4
108010000521 Human Growth Hormone Proteins 0.000 description 4
102100036532 Interferon alpha-8 Human genes 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000037431 insertion Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
241000894007 species Species 0.000 description 4
230000014616 translation Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
102000002265 Human Growth Hormone Human genes 0.000 description 3
239000000854 Human Growth Hormone Substances 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
101150006914 TRP1 gene Proteins 0.000 description 3
LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
108010047126 interferon-alpha 8 Proteins 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
230000014621 translational initiation Effects 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101001034829 Homo sapiens Interferon alpha-10 Proteins 0.000 description 2
101001034828 Homo sapiens Interferon alpha-14 Proteins 0.000 description 2
101000959704 Homo sapiens Interferon alpha-5 Proteins 0.000 description 2
102100039734 Interferon alpha-10 Human genes 0.000 description 2
102100039733 Interferon alpha-14 Human genes 0.000 description 2
102100039948 Interferon alpha-5 Human genes 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
108090000467 Interferon-beta Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
101100122010 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) glmM gene Proteins 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
210000003771 C cell Anatomy 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108010088874 Cullin 1 Proteins 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241001522878 Escherichia coli B Species 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
-1 Klenow et al. Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
241000556720 Manga Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
241001442654 Percnon planissimum Species 0.000 description 1
101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000607720 Serratia Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
239000008051 TBE buffer Substances 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000007792 addition Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
101150118163 h gene Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
QCOXCILKVHKOGO-UHFFFAOYSA-N n-(2-nitramidoethyl)nitramide Chemical group [O-][N+](=O)NCCN[N+]([O-])=O QCOXCILKVHKOGO-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000012807 shake-flask culturing Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000015096 spirit Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Public Health (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SE8106641A 1980-11-10 1981-11-09 Hybrida humanleukocyt interferoner, dna-sekvens kodande foer dem, vektor innehaallande dna-sekvensen samt farmaceutisk komposition innehaallande hybrida humanleukocytinterferonerna SE460539B (sv)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20557980A	1980-11-10	1980-11-10
US06/237,388 US4414150A (en)	1980-11-10	1981-02-23	Hybrid human leukocyte interferons
US06/305,657 US4456748A (en)	1981-02-23	1981-09-25	Hybrid human leukocyte interferons

Publications (2)

Publication Number	Publication Date
SE8106641L SE8106641L (sv)	1982-06-24
SE460539B true SE460539B (sv)	1989-10-23

Family

ID=27394813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8106641A SE460539B (sv)	1980-11-10	1981-11-09	Hybrida humanleukocyt interferoner, dna-sekvens kodande foer dem, vektor innehaallande dna-sekvensen samt farmaceutisk komposition innehaallande hybrida humanleukocytinterferonerna

Country Status (34)

Country	Link
EP (1)	EP0051873B1 (fr)
JP (1)	JP2642291B2 (fr)
KR (1)	KR920007439B1 (fr)
AT (1)	ATE46718T1 (fr)
AU (1)	AU555293B2 (fr)
BR (1)	BR8107293A (fr)
CA (2)	CA1212915A (fr)
CH (2)	CH660743A5 (fr)
DE (2)	DE3144469A1 (fr)
DK (1)	DK173590B1 (fr)
DO (1)	DOP1981004064A (fr)
DZ (1)	DZ350A1 (fr)
ES (2)	ES506955A0 (fr)
FI (1)	FI79550C (fr)
FR (1)	FR2493867B1 (fr)
GB (1)	GB2090258B (fr)
GR (1)	GR81947B (fr)
HK (1)	HK51685A (fr)
IE (1)	IE51850B1 (fr)
IL (1)	IL64243A (fr)
IT (1)	IT1169276B (fr)
KE (1)	KE3536A (fr)
LU (1)	LU83745A1 (fr)
MC (1)	MC1424A1 (fr)
MY (2)	MY8700710A (fr)
NL (1)	NL189092C (fr)
NO (1)	NO165201C (fr)
NZ (1)	NZ198906A (fr)
PH (1)	PH18565A (fr)
PL (1)	PL233748A1 (fr)
PT (1)	PT73955B (fr)
SE (1)	SE460539B (fr)
YU (1)	YU46597B (fr)
ZW (1)	ZW26981A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH651308A5 (de) *	1980-07-01	1985-09-13	Hoffmann La Roche	Interferone und deren herstellung.
EP0085693A1 (fr) *	1981-08-14	1983-08-17	A/S Alfred Benzon	Sujets concernant des proteines du sous-type de l'interferon alpha humain et anticorps correspondants
EP0072541A3 (fr) *	1981-08-14	1984-04-18	F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft	Interferons de leucocytes humains, procédé pour leur production microbiologique, intermédiaires et compositions les contenant
GB2108510B (en) *	1981-10-03	1984-12-12	Ciba Geigy Ag	Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
IT1167610B (it) *	1982-01-19	1987-05-13	Cetus Corp	Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
DE3220116A1 (de) *	1982-05-28	1983-12-01	Dr. Karl Thomae Gmbh, 7950 Biberach	Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
IE56509B1 (en) *	1982-11-04	1991-08-28	Univ California	Methods for oncogenic detection
US4751287A (en) *	1983-02-24	1988-06-14	Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr	Human leukocyte interferon N and a method of producing same in bacterial cells
GB8315980D0 (en) *	1983-06-10	1983-07-13	Biogen Nv	Producing hybrid dna sequences
GB8317880D0 (en) *	1983-07-01	1983-08-03	Searle & Co	Structure and synthesis of interferons
US4892743A (en) *	1983-12-21	1990-01-09	Schering Corporation	Novel hybrid interferon species
EP0146903A3 (fr) *	1983-12-19	1987-07-22	Schering Corporation	Production d'un vecteur qui encode un interféron hybride
DE3409966A1 (de) *	1984-03-19	1985-09-26	Hoechst Ag, 6230 Frankfurt	Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
JPS6156199A (ja) *	1984-08-27	1986-03-20	Shionogi & Co Ltd	新規ヒトインタ−フエロンα類
EP0173935A1 (fr) *	1984-08-31	1986-03-12	University Patents, Inc.	Interférons humains d'hybrides de lymphoblastoides-leucocytes
DE3434345A1 (de) *	1984-09-19	1986-03-27	Hoechst Ag, 6230 Frankfurt	Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
EP0194006B1 (fr) *	1985-02-01	1992-04-29	Imperial Chemical Industries Plc	Polypeptides analogues d'interféron, procédé pour les préparer et compositions pharmaceutiques les contenant
DE3685996T2 (de) *	1985-06-11	1993-01-14	Ciba Geigy Ag	Hybrid-interferone.
WO1987002037A1 (fr) *	1985-09-26	1987-04-09	Genetics Institute, Inc.	Proteines tensio-actives pulmonaires
US4806347A (en) *	1985-12-11	1989-02-21	Schering Corporation	Interferon combinations
EP0490233A1 (fr) *	1986-03-10	1992-06-17	BOEHRINGER INGELHEIM INTERNATIONAL GmbH	Anticorps monoclonaux contre les interférons hybrides Bgl III, leur application et leur procédé de préparation
DE3607835A1 (de) *	1986-03-10	1987-09-24	Boehringer Ingelheim Int	Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4851220A (en) *	1986-11-26	1989-07-25	Schering Corporation	Stable oleaginous gel
US4853218A (en) *	1987-02-24	1989-08-01	Schering Corporation	Zinc-protamine-alpha interferon complex
EP0331635A3 (fr) *	1988-02-29	1990-02-28	The Board of Regents of the University of Texas System	Préparation pour le traitement du cancer de la vessie
US5372808A (en) †	1990-10-17	1994-12-13	Amgen Inc.	Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
GB2273931A (en) *	1992-09-28	1994-07-06	Unilever Plc	Mutant polypeptides
JPH11507352A (ja)	1995-06-07	1999-06-29	ジンタ・インコーポレイテッド	新規カルバメート基本カチオン性脂質
TW442492B (en) *	1995-07-26	2001-06-23	Novartis Ag	Process for the enrichment of interferon
FR2823220B1 (fr)	2001-04-04	2003-12-12	Genodyssee	Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CA2498319A1 (fr)	2002-09-09	2004-03-18	Nautilus Biotech	Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US7314613B2 (en)	2002-11-18	2008-01-01	Maxygen, Inc.	Interferon-alpha polypeptides and conjugates
CA2566247A1 (fr)	2004-05-19	2005-12-01	Maxygen, Inc.	Polypeptides et conjugues interferon-alpha
MX2007014524A (es)	2005-05-18	2008-02-07	Maxygen Inc	Polipeptidos desarrollados de interferon-alfa.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CY1346A (en) *	1980-01-08	1987-01-16	Biogen Nv	Dna sequences,recombinant dna molecules and processes for producing human interferon-like polypeptides

1981
- 1981-11-07 ES ES506955A patent/ES506955A0/es active Granted
- 1981-11-09 EP EP81109579A patent/EP0051873B1/fr not_active Expired
- 1981-11-09 GR GR66464A patent/GR81947B/el unknown
- 1981-11-09 DE DE19813144469 patent/DE3144469A1/de not_active Ceased
- 1981-11-09 IL IL64243A patent/IL64243A/xx not_active IP Right Cessation
- 1981-11-09 MC MC811558A patent/MC1424A1/fr unknown
- 1981-11-09 DE DE8181109579T patent/DE3177106D1/de not_active Expired
- 1981-11-09 PT PT73955A patent/PT73955B/pt unknown
- 1981-11-09 CA CA000389688A patent/CA1212915A/fr not_active Expired
- 1981-11-09 PL PL23374881A patent/PL233748A1/xx unknown
- 1981-11-09 IE IE2622/81A patent/IE51850B1/en not_active IP Right Cessation
- 1981-11-09 AU AU77304/81A patent/AU555293B2/en not_active Expired
- 1981-11-09 GB GB8133762A patent/GB2090258B/en not_active Expired
- 1981-11-09 CH CH7174/81A patent/CH660743A5/de not_active IP Right Cessation
- 1981-11-09 FR FR8120943A patent/FR2493867B1/fr not_active Expired
- 1981-11-09 DK DK198104946A patent/DK173590B1/da active
- 1981-11-09 NZ NZ198906A patent/NZ198906A/en unknown
- 1981-11-09 SE SE8106641A patent/SE460539B/sv not_active Application Discontinuation
- 1981-11-09 DZ DZ816369A patent/DZ350A1/fr active
- 1981-11-09 NO NO813785A patent/NO165201C/no not_active IP Right Cessation
- 1981-11-09 CH CH5574/85A patent/CH663032A5/de not_active IP Right Cessation
- 1981-11-09 PH PH26462A patent/PH18565A/en unknown
- 1981-11-09 AT AT81109579T patent/ATE46718T1/de not_active IP Right Cessation
- 1981-11-10 ZW ZW269/81A patent/ZW26981A1/xx unknown
- 1981-11-10 KR KR1019810004343A patent/KR920007439B1/ko not_active Expired
- 1981-11-10 YU YU265681A patent/YU46597B/sh unknown
- 1981-11-10 IT IT24967/81A patent/IT1169276B/it active
- 1981-11-10 LU LU83745A patent/LU83745A1/de unknown
- 1981-11-10 DO DO1981004064A patent/DOP1981004064A/es unknown
- 1981-11-10 FI FI813539A patent/FI79550C/fi not_active IP Right Cessation
- 1981-11-10 BR BR8107293A patent/BR8107293A/pt unknown
- 1981-11-10 NL NLAANVRAGE8105078,A patent/NL189092C/xx not_active IP Right Cessation
1982
- 1982-05-19 ES ES512354A patent/ES512354A0/es active Granted
1984
- 1984-12-18 CA CA000470467A patent/CA1277616C/fr not_active Expired - Lifetime
1985
- 1985-05-21 KE KE3536A patent/KE3536A/xx unknown
- 1985-07-04 HK HK516/85A patent/HK51685A/xx not_active IP Right Cessation
1987
- 1987-12-30 MY MY710/87A patent/MY8700710A/xx unknown
1988
- 1988-12-30 MY MY66/88A patent/MY8800066A/xx unknown
1992
- 1992-12-28 JP JP4349148A patent/JP2642291B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK173590B1 (da)	2001-04-02
FI79550B (fi)	1989-09-29
NL189092B (nl)	1992-08-03
CA1277616C (fr)	1990-12-11
IE51850B1 (en)	1987-04-15
JP2642291B2 (ja)	1997-08-20
PT73955A (en)	1981-12-01
GB2090258A (en)	1982-07-07
SE8106641L (sv)	1982-06-24
DOP1981004064A (es)	1988-03-16
ES8302778A1 (es)	1983-02-01
YU265681A (en)	1984-08-31
NZ198906A (en)	1985-12-13
KR830007825A (ko)	1983-11-07
CH660743A5 (de)	1987-06-15
NL189092C (nl)	1993-01-04
KR920007439B1 (ko)	1992-09-01
EP0051873A2 (fr)	1982-05-19
YU46597B (sh)	1994-01-20
AU555293B2 (en)	1986-09-18
NO165201C (no)	1991-01-16
NO813785L (no)	1982-05-11
FI813539L (fi)	1982-05-11
ATE46718T1 (de)	1989-10-15
NO165201B (no)	1990-10-01
BR8107293A (pt)	1982-08-03
NL8105078A (nl)	1982-06-01
IL64243A (en)	1985-11-29
EP0051873A3 (en)	1982-09-22
PH18565A (en)	1985-08-09
IT1169276B (it)	1987-05-27
IT8124967A0 (it)	1981-11-10
ZW26981A1 (en)	1982-06-02
GB2090258B (en)	1984-05-02
FR2493867A1 (fr)	1982-05-14
DE3144469A1 (de)	1982-09-02
AU7730481A (en)	1982-05-20
FI79550C (fi)	1990-01-10
DE3177106D1 (en)	1989-11-02
FR2493867B1 (fr)	1986-06-27
GR81947B (fr)	1984-12-12
PL233748A1 (en)	1983-07-18
DK494681A (da)	1982-05-11
ES8304200A1 (es)	1983-03-01
HK51685A (en)	1985-07-12
MY8700710A (en)	1987-12-31
IL64243A0 (en)	1982-02-28
EP0051873B1 (fr)	1989-09-27
MY8800066A (en)	1988-12-31
CH663032A5 (de)	1987-11-13
KE3536A (en)	1985-06-07
PT73955B (en)	1983-11-23
LU83745A1 (de)	1983-09-01
CA1212915A (fr)	1986-10-21
MC1424A1 (fr)	1982-10-18
ES512354A0 (es)	1983-03-01
ES506955A0 (es)	1983-02-01
IE812622L (en)	1982-05-10
DZ350A1 (fr)	2004-09-13
JPH07308191A (ja)	1995-11-28

Legal Events

Date

Code

Title

Description

1998-03-30

NAV

Patent application has lapsed

Ref document number: 8106641-7

Format of ref document f/p: F

Publication	Publication Date	Title
US4678751A (en)	1987-07-07	Hybrid human leukocyte interferons
US4456748A (en)	1984-06-26	Hybrid human leukocyte interferons
DK173590B1 (da)	2001-04-02	Fremgangsmåde til fremstilling af et antiviralt polypeptid og at et dobbeltstrenget DNA, der omfatter en sekvens, der koder
CA1341569C (fr)	2008-03-25	Production microbienne d'interferon associe a des fibroblastes humains
DK173543B1 (da)	2001-02-05	Modent humant leukocytinterferon; en bakterie, der kan producere et sådant interferon, og en fremgangsmåde til fremstilling
US6610830B1 (en)	2003-08-26	Microbial production of mature human leukocyte interferons
EP0152613B1 (fr)	1991-03-20	Promoteur
JP2865423B2 (ja)	1999-03-08	サイトカイン型の活性を有するタンパク質、およびこのタンパク質をコード化する組換えｄｎａ、形質転換細胞および微生物
EP0104920B1 (fr)	1992-06-10	Séquences d'ADN, molécules d'ADN recombinantes et procédés pour la production des polypeptides semblables à l'hormone de la croissance du porc
GB2116980A (en)	1983-10-05	Human growth hormone variants
HU193512B (en)	1987-10-28	Process for preparing hybride interferones from human erythrocytes
GB2107718A (en)	1983-05-05	Human immune interferon
JPH0757190B2 (ja)	1995-06-21	酵母中でのポリペプチドの発現
HK160095A (en)	1995-10-20	Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon
EP0165654B1 (fr)	1993-01-13	Interleukine-1 purifiée
US4801685A (en)	1989-01-31	Microbial production of mature human leukocyte interferon K and L
EP0215576B1 (fr)	1992-04-01	Clonage et caractérisation du gène de l'interleukine-2 bovine
US5122459A (en)	1992-06-16	Gene encoding biologically active human interleukin 1
US4810645A (en)	1989-03-07	Microbial production of mature human leukocyte interferon K and L
EP0163603B1 (fr)	1989-12-13	Facteur humain de croissance de cellule-T
KR910009901B1 (ko)	1991-12-03	하이브리드 인간 백혈구 인터페론
NO165555B (no)	1990-11-19	Kunstig hybrid humant leukocytt-interferon-kodende dna-sekvens.
NO315003B1 (no)	2003-06-23	Fremgangsmåte for fremstilling av polypeptid samt DNA-sekvens som koder fordette
NO164178B (no)	1990-05-28	Plasmid som koder for et ferdigutviklet human leukocyttinterferon.